Tarlatamab (Imdelltra, Amgen) demonstrated superior overall survival in small cell lung cancer
In the global, Phase 3 DeLLphi-304 clinical trial1 evaluating Imdelltra® (tarlatamab-dlle) treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy,… read more.
